<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9949">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01948505</url>
  </required_header>
  <id_info>
    <org_study_id>00061838</org_study_id>
    <nct_id>NCT01948505</nct_id>
  </id_info>
  <brief_title>Effect of IV Acetaminophen on Patients in the Neurocritical Care Unit</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of an intravenous nonnarcotic pain medication on controlling patient
      pain.

      To assess the effect of an intravenous nonnarcotic pain medication on patient sedation
      levels in neurocritically ill patients.

      To assess the effect of an intravenous nonnarcotic pain medication on common side effects
      seen in patients taking other intravenous narcotic pain medication in the neurocritical care
      unit.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Level of pain as measured on the 0-10 Numeric Rating Scale (NRS)</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sedation level as measured on the Riker Scale (1-7)</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Frequency of nausea, vomiting, urinary retention &amp; constipation</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Post-operative Craniotomy Patients</condition>
  <condition>Carotid Endarterectomy and Carotid Artery Stenosis Patients</condition>
  <condition>Post-op Spine Patients Admitted to the NCCU</condition>
  <condition>Endovascular Patients Undergoing Intracranial Intervention</condition>
  <condition>Traumatic Brain Injuries NPO for at Least 12 Hours</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV acetaminophen: 1000mg IV q 8 hrs (scheduled) until: a) tolerating PO and IV saline-locked or b) 48 hours reached on medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV Normal Saline: 100ml IV q 8 hrs (scheduled) until: a) tolerating PO and IV saline-locked or b) 48 hours reached on medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous acetaminophen</intervention_name>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for IV acetaminophen</intervention_name>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 45 kg (amenable to adult dosing)

          -  all traumatic brain injuries NPO for at least 12 hours

          -  all post-operative craniotomy patients

          -  all non-operative subarachnoid hemorrhage, intraparenchymal hemorrhage, and stroke
             patients

          -  all carotid endarterectomy and carotid artery stenosis patients

          -  all endovascular patients undergoing intracranial intervention

          -  all post-op spine patients admitted to the NCCU

        Exclusion Criteria:

          -  documented allergy to acetaminophen

          -  documented severe hepatic impairment (Child-Pugh score &gt; 6) or severe hepatic disease
             (hepatitis)

          -  documented severe renal impairment (CrCl &lt; 30 ml/min) Blood tests will be performed
             prior to study procedures that will ensure patients do not have renal impairment.

          -  patients who are pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Walavan Sivakumar, MD</last_name>
    <phone>818-599-3570</phone>
    <email>walavan.sivakumar@hsc.utah.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Walavan Sivakumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 22, 2013</lastchanged_date>
  <firstreceived_date>September 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Walavan Sivakumar</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Craniotomy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carotid Stenosis</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
